Scinovex
articleTop 1% cited

Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel Randomized, Placebo-Controlled, Double-Blind Clinical Trials

Abstract

Recombinant FVIIa resulted in a significant reduction in RBC transfusion in severe blunt trauma. Similar trends were observed in penetrating trauma. The safety of rFVIIa was established in these trauma populations within the investigated dose range.

Trauma, Hemostasis, Coagulopathy, ResuscitationTrauma and Emergency Care StudiesHemophilia Treatment and ResearchMedicinePlaceboRecombinant factor VIIaPenetrating traumaSurgeryRandomized controlled trialBlood transfusionBlunt traumaAnesthesiaAdverse effect

MeSH terms

AdultDouble-Blind MethodFemaleHemorrhageHemostasisHumansMaleWounds and InjuriesFactor VIIaChi-Square DistributionTreatment OutcomeErythrocyte TransfusionStatistics, Nonparametric
Citations
782
FWCI
62.06
field-weighted impact
References
33
Percentile
100%
vs. same field & year
Citations per year
References
Recombinant Activated Factor VII for Adjunctive Hemorrhage Control in Trauma
The Journal of Trauma: Injury, Infection, and Critical Care · 2001 · 448 citations
Early Predictors of Postinjury Multiple Organ Failure
Archives of Surgery · 1994 · 486 citations
Platelet activity of high‐dose factor VIIa is independent of tissue factor
British Journal of Haematology · 1997 · 538 citations
Blood Transfusion
Archives of Surgery · 1997 · 565 citations
Epidemiology of trauma deaths
The American Journal of Surgery · 1980 · 848 citations
The American-European Consensus Conference On Ards. Definitions, Mechanisms, Relevant Outcomes, And Clinical Trial Coordination
American Journal of Respiratory and Critical Care Medicine · 1994 · 6,745 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel Randomized, Placebo-Controlled, Double-Blind Clinical Trials · Scinovex